Concepedia

JT Kost

JK

Statistics

Publications

4

Citations

452

H-Index

4

Active since

2007

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

JT Kost is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, human immunodeficiency virus pharmacotherapy, and antiviral agents.

Publications per year

2007–2009

4

Publications

4

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

Marian Iwamoto, LA Wenning, AS Petry et al. · Clinical Pharmacology & Therapeutics · 2007 · 170 citations

, , +17

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

DM Bloomfield, JT Kost, Kalyan Ghosh et al. · Clinical Pharmacology & Therapeutics · 2008 · 151 citations

, , +15

Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

LA Wenning, AS Petry, JT Kost et al. · Clinical Pharmacology & Therapeutics · 2009 · 90 citations

, , +17

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

Marian Iwamoto, JT Kost, G. C. Misty et al. · The Journal of Clinical Pharmacology · 2008 · 41 citations

, , +15

1–4 of 4